Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5348133 | 0.71 | — | — | |
| SCHEMBL630634 | 0.68 | HDAC6 (0.41) | KDM4CHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL7988951 | 0.66 | HDAC6 (0.40) | KDM4CHDAC1HDAC6 | |
| SCHEMBL366089 | 0.65 | HDAC1 (0.32) | HDAC1HDAC6 | |
| SCHEMBL4031802 | 0.64 | RAB9A (0.50) | — | |
| SCHEMBL3612034 | 0.64 | ALDH1A1 (0.46) | — | |
| SCHEMBL496792 | 0.64 | HDAC1 (0.31) | HDAC1HDAC6 | |
| SCHEMBL5104622 | 0.62 | CYP1A2 (0.30) | — | |
| SCHEMBL1327552 | 0.62 | HDAC1 (0.30) | HDAC1HDAC6 | |
| SCHEMBL451027 | 0.62 | KDM4C (0.34) | KDM4CHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | claimed |
| EP-1926712-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | claimed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | claimed |
| EP-1926712-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2007028131-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1373259-B1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| EP-0042569-B1 | 4,4-DISUBSTITUTED SPIRO-1,4-DIHYDROPYRIDINES, PROCESS FOR PRODUCING THEM AND THEIR USE AS INTERMEDIATES | BAYER AG (DE) | 1983-10-12 | — | — | EP | claimed |
| CN-115572252-A | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2023-01-06 | — | — | CN | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1926712-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-5871815-A | Antistatic film and method of manufacturing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0511650-B1 | Antistatic film and method of manufacturing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5695836-A | Antistatic film and method of manufacturing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1997-12-09 | — | — | US | disclosed |
| EP-0511650-A1 | Antistatic film and method of manufacturing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| US-5066800-A | For coupling cephalosporins to quinolines(or derivatives) | HOFFMANN-LA ROCHE INC. (US) | 1991-11-19 | — | — | US | disclosed |
| EP-0453952-A2 | A process for synthesizing cephalosporin compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1991-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | HTR2C, HTR2A, HTR1A | KDM4C 1034/4885HDAC1 1932/4885HDAC6 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.